Healthcare Realty Trust price target lowered to $19 from $23 at Stifel

Stifel analyst Stephen Manaker lowered the firm’s price target on Healthcare Realty Trust to $19 from $23 and keeps a Buy rating on the shares following the REIT’s Q3 report, which the firm sees “showing some early signs of the upswing” in the medical office building cycle. Larger leasing spreads and improving occupancy should lead to stronger NOI and bottom-line growth over the next few years, the analyst tells investors.